Table 2.
Univariate analysis of clinical variables predicting the risk of COVID‐19 in our cohort of IBD patients on biologic therapy
| Cases of COVID‐19 | Controls | Univariate analysis | |||
|---|---|---|---|---|---|
| OR | 95% CI | P | |||
| N | 7 | 1809 | — | — | — |
| Age, mean ± standard deviation | 55 ± 18 | 45 ± 14 | 1.0 | 1.0–1.1 | 0.09 |
| Male pts, n (%) | 3 (43) | 994 (55) | 0.6 | 0.1–2.8 | 0.52 |
| CD, n (%) | 3 (43) | 1174 (62) | 0.4 | 0.1–1.8 | 0.23 |
| Smokers, n (%) † | 3 (43) | 338 (31) | 3.3 | 0.6–20 | 0.19 |
| Disease duration, mean ± standard deviation | 12 ± 8 | 12 ± 9 | 1.0 | 0.9–1.1 | 0.99 |
| Non‐gut‐selective therapy, n (%) | 2 (29) | 1414 (78) | 0.1 | 0.1–0.6 | 0.01 |
| Comorbidities † | |||||
| Pulmonary | 1 (14) | 45 (3) | 5.6 | 0.6–48.9 | 0.12 |
| Cardiovascular | 2 (29) | 159 (12) | 3.6 | 0.6–19.7 | 0.14 |
†
When variables were not available for some patients, these were excluded for percentage calculation.
CI, confidence interval; IBD, inflammatory bowel disease; OR, odds ratio.